Format

Send to

Choose Destination
See comment in PubMed Commons below
Pharmacotherapy. 2015 Jan;35(1):28-33. doi: 10.1002/phar.1493. Epub 2014 Sep 30.

Adverse reactions associated with systemic polymyxin therapy.

Author information

  • 1Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia and Charleston, South Carolina.

Abstract

The systemic polymyxins, colistin and polymyxin B, are increasingly used for multidrug-resistant bacterial infections and have a long history of dose-limiting toxicity. This review summarizes the most recent available information about the mechanisms, incidence, risk factors, and minimization strategies for polymyxin toxicity. Nephrotoxicity is related to polymyxin exposure with both size of dose and length of therapy associated with frequency. Newer studies have questioned conventional thinking that the relative risk of nephrotoxicity is lower for colistin than polymyxin B, especially in light of evolving dosing practices. Neurotoxicities and hypersensitivity reactions are less common than nephrotoxicity. New techniques to minimize or avoid polymyxin toxicities are now emerging including a growing interest in clinical assays for therapeutic drug monitoring and the development of novel, less toxic agents (e.g., polymyxin derivatives) for the treatment of multidrug-resistant bacterial infections.

KEYWORDS:

colistin; polymyxin; polymyxin B; toxicity

PMID:
25266910
DOI:
10.1002/phar.1493
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center